“…A series of Phase III clinical trials have been completed for viloxazine ER demonstrating its safety and efficacy in reducing the symptoms of ADHD in children and adolescents (Nasser et al., 2020 ; Nasser, Liranso, Adewole, Fry, et al., 2021a ; Liranso, Adewole, Fry, Hull, Busse, et al., 2021 ). Moreover, a recent study in pediatric ADHD subjects demonstrated that the effect of viloxazine ER treatment on ADHD‐related functional impairment provides clinically meaningful improvements (Faraone, Gomeni, Hull, Busse, Melyan, Rubin, et al., 2021 ; Nasser, Liranso, Busse, et al., 2021 ).…”